Status:
COMPLETED
IL-6 as a Biomarker for Personalized Treatment of PR
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Brief Summary
Several studies have shown the relevance of the IL6 level before treatment or after 6 months, as a predictive biomarker for the persistence of remission. The IL6 assay is now routinely available using...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- 18 to 65 years old
- patients with rheumatoid arthritis according to 2010 ACR/EULAR criteria who have one of the following conditions:
- Subjects with active RA (DAS28\> 3.6) who have failed methotrexate treatement and with a standard medical care for which an indication for biotherapy is retained or
- Subjects with remission of RA (DAS28\<2.6) for which a biotherapy delay (anti-TNF or anti-IL6R or JAKi) is proposed.
- Exclusion criteria:
- \- Age under 18 years old
Exclusion
Key Trial Info
Start Date :
March 18 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04779983
Start Date
March 18 2021
End Date
August 1 2021
Last Update
October 19 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UH Montpellier
Montpellier, France, 34295